Cognitio

Artificial intelligence is already reshaping how regulatory professionals work—but with opportunity comes responsibility.In this episode of Cognitio, we bring you key insights from an ARCS webinar led by Kyle from GXP Vigilance, exploring how AI is being used across regulatory affairs, pharmacovigilance and quality environments, and what professionals need to understand to use it safely and effectively.This is not a conversation about hype. It’s about real-world application in regulated environments, where accuracy, accountability and patient safety cannot be compromised.• Why AI adoption is accelerating across the life sciences sector—and what that means for regulatory roles• The biggest risks of using AI, including hallucinations, fabricated citations and data leakage • The critical importance of human accountability in all AI-assisted outputs• Practical guidance on acceptable vs unacceptable uses of AI in regulated settings• How prompt engineering is evolving—and why it’s becoming a core professional skill• The difference between public AI tools and enterprise-grade solutions• What’s coming next in governance, policy and regulatory expectations for AIAI is a powerful tool—but it is not a source of truth.Human oversight remains essential. Regulatory professionals are still the final decision-makers and are accountable for all outputs. Using AI safely requires discipline. This includes avoiding confidential data, validating outputs and understanding the limitations of large language models.Prompting matters. The quality of input directly impacts the reliability of output, making structured prompting an increasingly valuable capability.Governance is coming. Organisations will need clear frameworks, policies and controls as regulatory expectations evolve.As AI becomes embedded in everyday workflows, regulatory professionals must strike a balance between efficiency and compliance.Those who understand both the capabilities and limitations of AI will be better positioned to lead in a rapidly changing environment—one where professionalism, judgement and trust remain central.ARCS Australia is the peak body for life sciences professionals, advancing capability across the sector through education, community and advocacy.🎧 Follow Cognitio for more conversations shaping the future of the life sciences sector🔗 Learn more at ARCS AustraliaWhat you’ll hear in this episodeKey takeawaysWhy this mattersAbout ARCS Australia

This week on Top 3 with Tim, ARCS CEO Dr Tim Boyle shares the biggest updates shaping the ARCS community and Australia’s life sciences sector.In this short update:• Final call for 2026 ARCS Annual Conference early bird registrations• ARCS announces its new partnership with the Australian Institute of Company Directors (AICD) and the upcoming LifeSciences Company Directors Course• Highlights from a huge week of sector engagement, including the sold-out Leadership Summit with MAPA, Melbourne member networking, and the Monash University careers roadshowTim also looks ahead to International Clinical Trials Day on 20 May, where ARCS will host a free online symposium focused on governance, AI, digital informed consent and the future of clinical trials in Australia.ARCS continues to champion professionalism, capability building and sector-wide connection across the full life sciences ecosystem.Join the conversation. Join ARCS today.

How do we separate misinformation from meaningful public health signals, and what happens when digital intelligence is combined with clinical evidence?In this episode of Cognitio, we explore how online sentiment, AI-powered surveillance and real-world healthcare data can work together to identify, investigate and validate emerging vaccine safety concerns.Dr Gerardo Luis Dimaguila, Informatics Lead at the Murdoch Children’s Research Institute and Data Innovation Lead at the Centre for Health Analytics, introduces VaxPulse, a digital surveillance learning health system developed since 2021. Using AI, social listening and advanced analytics, VaxPulse monitors vaccine-related concerns and misinformation across online platforms, helping public health professionals detect early warning signs and better understand the information environment shaping vaccine confidence.Aishwarya Shetty, epidemiologist and vaccine safety specialist at the Centre for Health Analytics, then demonstrates how these digital insights can be translated into rigorous epidemiological investigation. Using VaxPulse data identifying menstrual health concerns following COVID-19 vaccination, Aishwarya presents how large-scale GP syndromic surveillance and broader safety datasets were used to validate public concerns, assess risk and strengthen evidence-based communication.Together, this episode explores:• How AI and digital surveillance are reshaping pharmacovigilance• The growing role of social media as an early signal detection tool• How misinformation and genuine public concerns can be distinguished• The integration of digital signals with GP and clinical datasets• Why transparent, evidence-led communication is critical to vaccine trustThis episode is essential listening for professionals in pharmacovigilance, vaccine safety, epidemiology, regulatory affairs, public health and digital health innovation.Cognitio is ARCS Australia’s platform for thought leadership, professional development and sector-wide dialogue across the life sciences ecosystem.Join the conversation. Join ARCS today.

What does high performance really look like when it’s shaped by lived experience?In this episode of Cognitio, we explore the intersection between professional capability and chronic illness—and how navigating personal health challenges can fundamentally shape resilience, leadership, and perspective in the life sciences sector.Hosted by Anna Megalakakis from ARCS, this conversation brings together Mark Del Borgo from the Department of Pharmacology at Monash University and his PhD student Isabella Simon. Both are not only researchers, but also consumers of the healthcare system—offering a rare and powerful dual perspective from inside the science and the lived experience it ultimately serves.From the realities of diagnosis and long-term treatment, to the unseen pressures of maintaining performance in high-demand roles, this discussion highlights what often sits beneath the surface in our workplaces and research environments.It also raises important questions for the sector:How do we better support high performers managing chronic conditions?What does empathetic leadership look like in practice?And how can lived experience strengthen—not limit—professional contribution?This is a conversation about resilience, but also about understanding. About the human side of science, and the importance of creating environments where people can perform at their best—because they are supported, not despite their challenges.Living and working with chronic illness in life sciencesThe impact of diagnosis on career direction and ambitionNavigating research, academia, and health simultaneouslyEmpathy, leadership, and building high-performing teamsThe role of lived experience in shaping better science and outcomesAnna Megalakakis – ARCSMark Del Borgo – Department of Pharmacology, Monash UniversityIsabella Simon – PhD Candidate, PharmacologyARCS Australia is the peak body for the life sciences sector, supporting professionals across the full product lifecycle through education, professional development, and community.Key Topics CoveredFeatured in this EpisodeAbout ARCS

What can elite sport teach us about leadership in the workplace?In this episode of the Cognitio Podcast, Tim Boyle sits down with Tomek Szklarski, Head Coach of the Australian National Handball Team, to explore how high-performance sporting environments develop resilient leaders, build trust under pressure, and create cultures where teams thrive.Drawing on his experience as both a professional athlete and national coach, Tomek shares practical lessons from elite team sport that translate directly into leadership, management and team development within professional environments.Together, Tim and Tomek discuss:Why resilience matters more than talent in sustained high-performance environmentsThe transition from peer leadership to formal leadershipHow trust is built, broken and rebuilt under pressureWhy great leaders create capability rather than dependencyThe role of vulnerability and self-awareness in leadershipPractical strategies for developing resilience in yourself and othersWhether you lead a team, manage stakeholders, or are looking to strengthen your own professional resilience, this episode offers valuable insights into what it takes to lead when the pressure is on.Tomek Szklarski is Head Coach of the Australian National Handball Team and a former professional European handball player. He has represented Sydney University, New South Wales and Australia at elite levels of competition, and has played a key role in developing handball talent nationally. Tomek brings a unique perspective on leadership shaped by years of experience as both a player and coach in high-performance sporting environments.About the Guest

What does it really mean to design healthcare with patients?In this episode of the Cognitio Podcast, Georghien Wiley, ARCS Convener for the Patient Engagement Interest Area, leads a powerful and deeply personal discussion on patient co-creation.Through real-world experiences, this episode explores the realities of navigating the healthcare system in Australia, particularly for patients and carers in regional settings. From access challenges and fragmented care to the often-overlooked role of carers, the conversation highlights critical gaps between system design and lived experience.It also reframes a key idea for the life sciences sector:Lived experience is not supplementary to evidence. It is a form of expertise that should shape how we design services, clinical trials and patient support programs.Key themes explored include:• The impact of fragmented and uncoordinated care• The hidden burden and invisibility of carers• Health literacy and communication challenges• The importance of trust, equity and inclusion in co-design• Moving beyond tokenistic engagement to meaningful partnershipThis episode is essential listening for professionals across clinical research, regulatory affairs, medical affairs, pharmacovigilance and market access who are looking to embed patient-centred approaches into their work.

Cell and gene therapies such as CAR-T are transforming modern medicine, offering new treatment options for cancers and rare diseases. But getting these breakthrough therapies to patients is not straightforward.In this episode of the Cognitio Podcast, Warwick Shaw from Johnson & Johnson explores how advanced therapies move from regulatory approval to reimbursement in Australia. The discussion examines the role of the Medical Services Advisory Committee (MSAC), the National Health Reform Agreement, and the complex coordination between federal and state governments that influences patient access.The conversation also highlights the growing pipeline of cell and gene therapies, the use of outcomes-based reimbursement models, and the policy changes needed to ensure Australian patients can access these life-changing treatments sooner.

Three signals this week point to a sector at a turning point.Australia’s life sciences industry is accelerating—with stronger local capability, growing global engagement, and a more coordinated national R&D strategy taking shape.But there’s a critical question we need to address.As we move toward a more economically driven innovation model, how do we ensure health and medical research remains grounded in patient outcomes—not just commercial return?In this week’s Top 3, I cover:• The Ambitious Australia R&D strategy—and what it means for our sector• A major capability investment in clinical trials infrastructure here in Sydney• Why international partnerships will define our next phase of growthIf we get the balance right, we have a real opportunity to strengthen both our sector and outcomes for patients.

In this episode of Cognitio, Tim Boyle speaks with Dr Natalie Anderson about the evolving regulatory landscape for non-animal models in pharmaceutical development.We explore global reforms at the US FDA and European Medicines Agency, the application of the Three Rs, and how Australia’s TGA is responding to advances in organoids, organ-on-chip technologies and in silico modelling. The discussion covers regulatory acceptance pathways, policy shifts, funding challenges and what this means for sponsors and regulatory professionals.A must-listen for those working in regulatory affairs, nonclinical development and health policy as science and regulation continue to evolve.

In this episode of Cognitio, ARCS CEO Tim Boyle explores the behavioural science behind leadership, compliance and decision-making in regulated environments.Despite extensive training and detailed SOPs, deviations still occur. So what’s missing? This conversation dives into the psychology of identity-based leadership, the forgetting curve, grey zone decision-making, and how culture shapes compliance in clinical research, regulatory affairs and life sciences.If you work in clinical trials, medical affairs, pharmacovigilance, quality or regulatory, this episode will challenge how you think about training, integrity and performance under pressure.Leadership isn’t memory. It’s identity.#Leadership #ClinicalResearch #RegulatoryAffairs #Pharmacovigilance #LifeSciences #ProfessionalDevelopment

What are the three biggest developments shaping Australia’s life sciences sector this week?In this short weekly briefing, ARCS CEO Tim Boyle shares the top stories from across the medicines, medical devices and clinical research ecosystem.This week’s episode covers:• A major step toward professional standards and competency-based accreditation for the clinical trials workforce following discussions at the A-CTEC conference• Updates from the ARCS community and national networking events, including the return to Perth and the latest Brisbane event• Why professional recognition in life sciences is becoming increasingly important, with applications now open for the ARCS College of FellowsThe episode also recognises International Women’s Day, highlighting the extraordinary contribution women make across the life sciences sector, including the fact that 73% of ARCS members are women.This short weekly podcast provides a fast overview of the key developments in Australia’s pharmaceutical, biotechnology, medtech and clinical trials sectors.ARCS members receive the full weekly life sciences news summary, so if you want to stay fully across what’s happening in the sector, consider joining ARCS.

What changes when a therapy moves from clinical trials to the real world?In this episode of the Cognitio podcast, ARCS Australia CEO Tim Boyle speaks with Carl Bufe about the critical differences between clinical development safety management and post-market pharmacovigilance.From SUSAR reporting and ICH E6 to ICH E2D, signal detection, spontaneous adverse event reporting and scaling safety systems, this discussion explores how compliance, data volumes, accountability and risk management evolve across the product lifecycle.Essential listening for professionals in regulatory affairs, clinical research, medical affairs and drug safety.Join the conversation. Join ARCS.

This week in Australian life sciences: a $1.6B digital health acquisition, global momentum in cell and gene therapy, AI in regulatory affairs, and registrations opening for the 2026 ARCS Annual Conference.In this short episode, Tim Boyle breaks down the top 3 stories shaping biotech, medtech, clinical trials and therapeutic product commercialisation across Australia and the Asia-Pacific.Fast insights. Big implications. Stay ahead of the sector.#lifesciences #biotech #medtech #clinicaltrials #regulatoryaffairs

Cell and gene therapies are transforming medicine — from CAR-T in oncology to next-generation gene therapies targeting rare disease.Ahead of the ARCS–DIA Cell & Gene Therapy Summit, Tim Boyle and Anna Megalakakis unpack Australia’s advanced therapies landscape. They explore manufacturing capability, workforce shortages, funding reform, regulatory pathways, and whether Australia can scale beyond clinical trials to become a regional CGT leader.A practical, strategic discussion for regulators, industry professionals, scientists and clinical research leaders.🎧 Listen now to understand where Australia stands — and what must happen next.

This week’s ARCS sector update covers three major developments shaping Australia’s medtech and pharmaceutical landscape.We unpack the AMR 2026 Summit in Sydney and the release of the Sixth AURA Report, highlighting why antimicrobial resistance is now an economic and national resilience issue.We examine the surge in PBS activity, with more than 20 medicines nearing listing decisions, and what this means for oncology, biosimilars and HTA reform.And we explore Australia’s advanced therapies momentum, as Peter MacCallum Cancer Centre doses the first patient in a locally developed CD19 CAR T trial.What do these shifts mean for regulatory, clinical, market access and quality professionals?Listen now to stay ahead of the signals shaping 2026.

South Korea has rapidly established itself as one of the world’s leading destinations for clinical research. With dense urban populations, advanced hospital infrastructure and a highly structured regulatory framework, it is now consistently ranked among the top countries globally for clinical trial activity.In this episode of the Cognitio Podcast, we explore what makes South Korea such a compelling jurisdiction for multinational development programs. Joining us from Seoul are Sophia Choi, Country Lead at ClinActis Korea, and Sophie and Soun from Bayer Korea’s pharmacovigilance team.Together, they unpack the practical realities of running clinical trials in Korea. We discuss MFDS approval pathways, IND timelines, translation requirements, import permits and contracting considerations. The conversation then turns to safety reporting, including SUSAR timelines, DSUR submission requirements and the implementation of ICH E2B R3 electronic reporting with Korean-specific data extensions.For ARCS members working in regulatory affairs, clinical operations or pharmacovigilance, this episode provides a grounded and practical overview of how Korea’s system operates and what sponsors need to consider when incorporating Korea into a global program.If you are involved in multinational trials or global safety reporting, this is an episode not to miss.

Global recognition for the TGA.PBS tensions escalating into legal action.And major leadership shifts across pharma.In this episode, Tim Boyle breaks down the three biggest stories shaping Australia’s life sciences sector this week — and why they matter for regulatory affairs, market access, clinical research and pharma professionals.What does WHO recognition mean for the TGA’s global influence?Is PBS policy entering a new phase of tension?And what do executive changes signal about sector recalibration?If you work in medtech, pharma or biotech, this is your weekly sector briefing.

Advancing LGBTQIA+ Inclusion in Healthcare and ResearchIn this episode of Cognitio, ARCS Australia CEO Tim Boyle explores why LGBTQIA+ inclusion is no longer optional in healthcare, clinical research, and the life sciences sector.Drawing on insights from an ARCS webinar featuring guests from Proud Science Alliance and ACON, this episode unpacks the real-world consequences of under-representation, data gaps, and systemic barriers faced by LGBTQIA+ communities. From social determinants of health and minority stress, to exclusionary research protocols and gaps in workforce training, the discussion highlights how invisibility in data leads directly to inequity in outcomes.The episode also examines emerging progress, including regulatory and policy shifts, evolving expectations for inclusive clinical trials, and what national workforce data reveals about allyship, wellbeing, and organisational culture across healthcare and medtech sectors.This is a practical, evidence-informed conversation for professionals working in medicines development, clinical research, healthcare delivery, and policy, focused on translating inclusion from principle into action.Inclusive research is ethical research. Inclusive healthcare delivers better outcomes for everyone.

A big week for policy, funding and medicine access.In this episiode, I break down my top three life sciences stories for the week and why they matter for Australia’s sector.ARCS members get the full weekly briefing via email. Join ARCS to stay across what matters.

🎙️ ARCS Weekly News Wrap — Final Episode of 2025Tim and Anna team up for the final Weekly News Wrap of the year, bringing you the most significant stories shaping Australia’s life sciences landscape. This fast, engaging episode covers the biggest pharma leadership moves, biotech breakthroughs, rare disease reform, PBS milestones, digital health shake-ups, and major medtech developments — including CSL’s new vaccine manufacturing facility.You’ll also hear key ARCS updates: new strategic partners, upcoming summits, professional development offerings, and a final call for 2026 ARCS Annual Conference abstracts.To wrap up the year, Tim and Anna share brief insights on what this week’s news means for the sector and what’s ahead for 2026.In this episode:• Pharma leadership changes and PBS highlights• Breakthroughs in biotech and clinical innovation• Medtech and vaccine capability advancements• Rare disease strategy momentum and genomics reform• Digital health transformation risks• ARCS announcements, events and partnershipsA sharp and informative send-off to 2025 — designed to keep you connected, informed and ready for the year ahead.Thanks for listening throughout 2025. Join ARCS in 2026 and be part of Australia’s growing community of life sciences professionals.

Inclusive clinical research is not a box to tick. It is a way of working.In this episode of the Cognitio Podcast, Tim Boyle is joined by webinar presenters Jane Gaunson, Olivia Payne, Mariam Hachem and Bernard Kelly-Edwards to explore practical strategies for partnering with Aboriginal and Torres Strait Islander communities in clinical research.The conversation highlights the role of the Victorian Aboriginal Community Controlled Health Organisation (VACCHO) and the guiding principles of marra mgarrgoo, marra goorri — the Victorian Aboriginal Health, Medical, and Wellbeing Research Accord — as a pathway to embed cultural safety and self-determination in research practice. The team also shares lessons from the Flash GM study, including what co-design looks like on the ground, why relationships and trust must come first, and how culturally informed consent approaches can strengthen participant understanding and engagement.Whether you’re a sponsor, CRA, site leader, investigator, ethics professional or work in governance, this episode offers grounded insights to help clinical trials deliver research that is respectful, relevant, and genuinely impactful.Brought to you by ARCS Australia.

In this week’s ARCS Weekly News Wrap, Tim Boyle unpacks the headlines shaping Australia’s medicines, medtech and biotech sectors, with a sharp eye on what they mean for professionals working across the product lifecycle. We cover key policy and reimbursement signals, regulatory and manufacturing developments, notable biotech and medtech milestones, and the people moves that hint at where the market is heading next.You’ll also hear a quick ARCS update from across the community, plus a practical wrap-up on how this week’s news could influence investment, strategy, workforce decisions and day-to-day execution in the sector.If you want to stay informed, build capability, and connect with the people doing the work, join ARCS as a professional member or explore enterprise membership for your organisation.#ARCSAustralia #ClinicalResearch #RegulatoryAffairs #MedicalAffairs #Pharmacovigilance #Medtech #Biotech #Pharma #HealthEconomics #Workforce #ProfessionalDevelopment

In this episode of the Cognitio Podcast, Tim Boyle introduces a powerful conversation on innovation, access, and equity in clinical trials. Featuring Julia Linda from Eli Lilly Australia and Melissa Reilly from Heart of Australia, the episode explores how clinical research can be delivered to regional, rural, and First Nations communities through innovative models and strong cross-sector partnerships.Julia shares the unmet needs she sees across Australian clinical research, and how thoughtful innovation can expand access to under-represented populations. Melissa provides an inside look at Heart of Australia’s mobile specialist service and the creation of the Heart of Australia Research Institute—bringing cutting-edge clinical trials to communities that typically miss out.Together they reveal what it takes to build, operationalise, and sustain clinical trials outside metropolitan centres, and why this work is essential for health equity and representative research.A must-listen for clinical researchers, sponsors, CROs, healthcare professionals, and anyone passionate about improving access to innovation across Australia.

In this week’s ARCS Weekly News Wrap, Tim Boyle recaps a major week for Australia’s life sciences sector during National Clinical Trials Week. The episode covers key developments across pharma, medtech, biotech, policy and investment, along with insights from ARCS’ activities in Melbourne, including the launch of the Clinical Workforce White Paper, the new ARCS and MAPA strategic alliance, and sector input into the national One Stop Shop.Tim also explores the biggest industry stories of the week, from global acquisitions and breakthrough imaging technology to advancing clinical trials and company milestones. The episode closes with reflections on the momentum across the sector and an invitation for professionals and employers to join the ARCS community.Listen for a clear and engaging overview of the trends shaping Australia’s life sciences landscape.

In this episode of the Cognitio Podcast, host Tim Boyle explores one of the most critical equity challenges in Australian healthcare: ensuring safe, effective, culturally informed use of medicines for First Nations peoples.Tim is joined by four respected leaders in medicine safety: Karen Battat (AstraZeneca), Vinham Mehta (Novartis), Marcela Bade (former TGA pharmacovigilance inspector) and Matt Iglesias, who together unpack the unique risk factors, data gaps and cultural considerations that influence pharmacovigilance in First Nations communities.The conversation highlights why First Nations representation in safety data remains low, the impact this has on signal detection and patient outcomes, and what meaningful, practical steps the sector can take — from culturally grounded educational materials to strengthened community partnerships and more robust system design.This episode is essential listening for anyone working in regulatory affairs, pharmacovigilance, clinical operations, public health or industry leadership. It’s a powerful reminder that medicine safety is not just a technical obligation, but a commitment to fairness, respect and culturally responsive practice.Join the ARCS community as a Professional Member — or bring your whole organisation on board — to stay connected, informed and engaged with the conversations shaping the future of the life sciences sector.

This week’s wrap brings you the biggest developments across Australia’s life sciences sector — all in one quick, engaging update. We cover major pharma moves, medtech breakthroughs, biotech investment momentum, regulatory updates, and the latest people movements shaping the industry.From gene therapy and GLP-1 dealmaking to AI in radiology and standout Australian clinical results, this episode highlights the trends influencing policy, access, capability and commercialisation right now.If you want to stay informed, connected and ahead of sector shifts, this is the update you don’t want to miss.Watch now and get the week’s essential insights — fast.

What is Intellectual Property? A Practical Guide for Australia’s Life Sciences SectorIn this episode of Cognitio, Tim Boyle takes listeners on a clear and engaging tour of the intellectual property landscape, guided by three specialists from Spruson and Ferguson Lawyers. IP sits at the core of innovation and commercialisation in the life sciences, yet it is often misunderstood or overlooked until problems arise. This conversation breaks it down in a way that is accessible, practical, and directly relevant to researchers, clinicians, entrepreneurs, and anyone navigating discovery-to-market pathways.Dr Katherine Winbanks opens with an IP 101 masterclass, covering patents, trade marks, copyright, confidential information, and the risks of early disclosure. Sylvie Tso then steps through the commercialisation process, unpacking licensing, assignments, royalties, valuation challenges, and how to structure deals that actually create value. Finally, Katrina Crooks explains what happens when IP is infringed and how disputes are managed, from demand letters to litigation, injunctions, and enforcement of rights.Across the episode, the message is clear: strong IP strategy is essential for protecting innovation, attracting investment, and strengthening Australia’s position as a global life sciences leader.If you work in research, biotech, medtech, clinical trials, or commercialisation, this is an episode you won’t want to miss.

In this week’s episode, Anna Megalakakis steps behind the mic to bring you a fast-paced and insightful roundup of the biggest developments across Australia’s life sciences sector. From blockbuster pharma shifts and cutting-edge medtech launches to biotech investment momentum and major leadership movements, this episode unpacks what matters — and why.Anna also shares the latest from ARCS, including highlights from the HBA Sydney anniversary event, updates on the National Clinical Trials Governance Framework consultations, and fresh opportunities to get involved in the 2026 ARCS Annual Conference and the newly expanded 2025 Clinical Summit. Plus, hear about ARCS’ brand-new Enterprise Partnership model, offering organisations a powerful way to invest in their people.In this episode:Pharma: Tirzepatide’s global rise, PBS expansions, and shifting clinical trial landscapes.Medtech: AI-powered imaging tech, next-gen valves, and long-term innovation partnerships.Biotech & Investment: Capital milestones, regulatory progress, and clinical breakthroughs.People Movement: Key promotions, awards, and leadership shifts across the sector.Partner With ARCS: How enterprise memberships can elevate your workforce and brand.Whether you work in clinical trials, regulatory affairs, medical affairs, biotech, medtech, policy, or beyond — this episode gives you the insights you need to stay ahead.Listen now and stay connected to the news shaping Australia’s life sciences future. And if you haven’t already — now’s the perfect time to join ARCS Australia and be part of the country’s largest professional community in our sector.

In this episode of The Cognitio Podcast, ARCS Australia CEO Tim Boyle introduces highlights from a thought-provoking ARCS Interest Area webinar, Automating Life Science Workflows through AI, presented by Dr Rishi Verma, CEO and Founder of Stethy AI.Dr Verma, a physician and engineer, takes listeners inside the fast-evolving world of artificial intelligence in the life sciences. Drawing directly from his presentation, he explains — in his own words — how AI is transforming the daily realities of regulatory affairs and pharmacovigilance, from document authoring and quality control to horizon scanning and compliance monitoring.Through real-world examples, including a compelling case study from Roche, Dr Verma demonstrates how AI can reduce manual workloads, improve accuracy, and accelerate submissions — while keeping human expertise firmly at the centre of every decision.This episode is a must-listen for regulatory professionals, clinical researchers, and anyone navigating the intersection of technology, compliance, and patient safety.🎧 Tune in to learn how AI is reshaping the way we work — not by replacing professionals, but by empowering them to focus on strategy, quality, and innovation.

This week’s episode dives into the biggest stories shaping Australia’s life sciences landscape — from global leadership milestones to biotech breakthroughs and policy reform.We celebrate Professor Tony Lawler’s appointment as Global Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA), marking Australia’s growing influence in global regulatory science.In pharma, Takeda, Pfizer, and Boehringer Ingelheim make bold moves, while new funding under the Life Saving Drugs Program delivers long-awaited hope for rare disease patients.The biotech sector surges ahead with the opening of Australia’s first Viral Vector Manufacturing Facility in Westmead and major international deals, including Novartis’s $18.4B acquisition of Avidity Biosciences.Meanwhile, medtech innovation keeps pace as CSL Seqirus expands its global vaccine partnerships and Medicare boosts access to diagnostics.Plus, we spotlight leadership shifts at AbbVie, Uniseed, and PolyNovo, and Nav Lee’s representation of ARCS on the world stage in Cairo.🎧 Tune in for insights, context, and commentary on how these developments are shaping Australia’s clinical trials, biotech, and medtech future.

Next Generation Nuclear Medicine: Powering the Future of Precision HealthIn this episode of ARCS Cognitio, ARCS Australia CEO Tim Boyle leads a compelling conversation on the rapidly evolving world of next-generation nuclear medicines — where physics meets biology to transform how we diagnose and treat disease.Joined by a panel of industry leaders — Christian Behrenbruch (Telix Pharmaceuticals), David James (formerly Sirtex Medical and OncoSil), Rosanne Robinson (Clarity Pharmaceuticals, ex ANSTO, and Cylotek), and Brad Walsh (Glytherix) — the discussion explores the technologies, supply chain challenges, and investment opportunities shaping the future of this dynamic sector.From emerging isotopes and theranostics to Australia’s unique position as a regional hub for radiopharmaceutical innovation, this episode offers deep insights into one of the most exciting frontiers in modern medicine.Tune in to discover how collaboration, capability, and clinical excellence are driving the next era of nuclear medicine — and how Australia can lead the charge.🎧 Listen now and join the conversation at arcs.com.au.

ARCS Weekly News Wrap – Week Ending 25 October 2025This week’s episode covers a powerhouse mix of policy shifts, scientific breakthroughs, and leadership changes shaping Australia’s life sciences landscape.Join Tim Boyle, CEO of ARCS Australia, as he unpacks:Pharma: Landmark PBS listings, proactive pharmacovigilance, and new rare disease breakthroughsMedtech: HTA review tensions, hospital funding reform, and insights from the MTAA ConferenceBiotech & Investment: A wave of clinical trials, capital raises, and global research collaborationsPeople Movement: Leadership transitions at Gilead, Moderna, and Omico that will influence the sector’s next chapterPartner with ARCS: How collaboration continues to drive innovation and workforce capability across the life sciences ecosystemIt’s a fast-paced, insightful wrap of the week’s most important developments — helping you stay informed, connected, and ahead of the curve.🎥 Watch the full episode now and don’t miss your chance to be part of the only professional network that connects every corner of the Australian life sciences sector.👉 Join ARCS today: www.arcs.com.au/join#ARCSWeeklyWrap #LifeSciences #Pharma #Medtech #Biotech #ARCSAustralia #ARCS2025Leaders

In this week’s ARCS Weekly News Wrap, Tim Boyle returns from Adelaide after the KCA Conference to bring you the top stories shaping Australia’s life sciences sector.This episode covers:• Pharma: FDA approval for MSD’s subcutaneous Keytruda, Eli Lilly’s oral obesity drug heading to the TGA, and J&J’s Stelara patent challenge.• Medtech: AI-assisted diagnostics at Macquarie University and Optain Health’s new Melbourne research hub.• Biotech and Investment: Momentum from Clarity Pharmaceuticals, Telix, and Chimeric Therapeutics as local innovation continues to accelerate.• People Movement: Leadership changes across Novartis, Boehringer Ingelheim, and Boston Scientific.Tim also reminds listeners that early bird pricing for the ARCS Clinical Summit closes 20 October and that places are still available for the upcoming Pharmacovigilance Inspections course.Stay informed, stay connected, and join the conversation with ARCS Australia – the professional home for Australia’s medtech and pharmaceutical sector.#ARCSAus #Pharma #Medtech #Biotech #LifeSciences #ClinicalResearch #ARCSWeeklyNewsWrap

This week’s ARCS Weekly News Wrap dives into the biggest stories shaping pharma, medtech, biotech, and the workforce behind them. From the MAPA-MAPS Summit and student careers fairs to global debates over paracetamol, robotic surgery innovations, and major biotech funding deals — we break it all down and explain what it means for you.Highlights include:The rise of medical affairs and ARCS’ careers outreachPharma headlines from Trump to the TGACutting-edge medtech adoption and diagnostic breakthroughsNext-gen biotech therapies and major investment winsSanofi’s HQ move, workforce pay trends, and hot skills in demandNew ventures and global collaborations driving patient-centred innovationStay informed, stay connected, and join ARCS to be part of the professional community leading Australia’s medtech, pharma, and biotech sectors forward.

In this episode of the Cognitio Podcast, Goce Bogeski FMPP shares his reflections on the often-overlooked similarities between pharmaceuticals and medical devices. Drawing on years of experience across both fields, he explains how market access processes converge, where inefficiencies exist, and why evidence plays such a critical role in reimbursement decisions. From the challenges of the prosthesis list to the differences in trial design, Goki highlights what really matters: patient outcomes, cost-effectiveness, and the science that underpins it all.He also leaves us with a powerful message.... that skills are transferable, opportunities are abundant, and collaboration across disciplines is essential for getting therapies to patients faster. Whether you’re in clinical trials, regulatory affairs, or market access, this episode will remind you that we are all part of one process, united by the same aim.

Weekly News Wrap – 19 September 2025This week’s ARCS Weekly News Wrap is packed with sector-shaping stories across pharma, medtech, biotech, and leadership. Tim Boyle recaps a milestone few days for ARCS, including a sold-out Leadership & Communications Symposium and a record turnout at our networking night with AMWA.In pharma, Australian science takes the global stage with Pfizer’s breast cancer trial and CSL’s billion-dollar play with Dutch biotech VarmX. Medtech sees big advances as Epworth Eastern adopts robotic bronchoscopy, Siemens Healthineers launches a $9M MRI facility with the University of Sydney, and Avita Medical secures European approval for its RECELL GO device.Biotech breakthroughs abound, with Oncosil, Alterity Therapeutics, Actinogen Medical, and Cleo Diagnostics all reporting promising progress, while Novartis doubles down on acquisitions. Leadership shifts at Ipsen, Clinigen, CSL, and Lilly round out the week, signalling fresh strategies in the sector.Join us as we unpack what these developments mean for you and why being part of the ARCS community matters more than ever.

Australia’s R&D Tax Incentive is one of the most significant programs driving investment and innovation in the life sciences. But how does it really work in practice, and what do the latest transparency data tell us about the companies claiming it?In this episode of the ARCS Cognitio Podcast, host Tim Boyle brings you highlights from a recent ARCS webinar with experts from EY. Together they unpack:The first tranche of R&D Tax transparency data and what it means for biotech, medtech, and clinical research.How companies can structure their claims and avoid common pitfalls.Key differences between Australian-owned and foreign-owned R&D arrangements.What regulators are focusing on in their compliance reviews.Whether you’re part of a multinational pharma, a startup biotech, or a contract research organisation, this episode provides practical insights into maximising the benefit of the R&D Tax Incentive while staying compliant.Listen now to understand how the program can support your organisation—and where the risks lie.

This week’s ARCS Biopharma & Medtech Wrap dives into the biggest headlines shaping the life sciences sector – from pharma restructures and drug pricing debates to medtech innovation and Australian biotech success stories.We cover:Pharma: Novo Nordisk’s 9,000 job cuts, Lundbeck’s global exits, Takeda’s narcolepsy breakthrough, and the growing debate on PBS and international drug pricing.Medtech: A $160m investment in robotics and AI in Sydney, plus Professor Edward Holmes’ award-winning AI and genomics research.Biotech & Investment: Cartherics and HaemaLogiX shine at the Asia Pacific Cell & Gene Awards, while local biotechs secure funding and approvals.People Movement: Leadership changes at Novartis and BeOne, and Daiichi Sankyo’s recognition as a top employer.We’ll unpack what it means for you – from clinicians and researchers to policy specialists and industry leaders. Plus, we connect the dots to upcoming ARCS events: the Leadership & Communication Symposium (18 Sept, Sydney) and the Global Cell & Gene Summit (25 Feb 2026, Sydney).🎧 Tune in for insights, context, and commentary on the news that matters to Australia’s life sciences community.👉 Join the conversation. Join ARCS today: arcs.com.au

In this episode of the ARCS Cognitio Podcast, we explore the regulatory framework for in vitro diagnostic (IVD) medical devices with international regulatory affairs expert Dr Adel Schneider.IVDs—from pregnancy tests to advanced blood screening assays—play a critical role in healthcare by providing the information that guides diagnosis and treatment. But how do regulators ensure these devices are safe, reliable, and trustworthy?Dr Schneider takes us through the key elements of IVD regulation, including definitions, classifications, essential principles, clinical evidence, quality systems, and post-market surveillance. With more than 30 years’ experience working across Europe, Asia Pacific, the Middle East and Africa, she offers a clear overview of the global regulatory landscape and why trust in IVDs is so vital.Join us as we unpack the complexities of IVD regulation and its impact on patients, professionals, and the broader life sciences community.

This week on the ARCS Weekly Life Sciences Wrap, we unpack the stories driving the future of medicine, policy, and innovation in Australia. From Canberra to the clinic, it’s been a week of breakthroughs, delays, and bold moves.Health Minister Mark Butler has finally announced the first steps toward reforming Australia’s Health Technology Assessment system — a long-awaited shift that could change how patients access medicines. We explore what this means for industry, clinicians, and patients.We also take you inside the ARCS Clinical Research Workforce Summit, where over 80 leaders came together to tackle the workforce constraints holding back Australia’s clinical trial sector. Plus, we spotlight upcoming ARCS events — including the Leadership & Communication Symposium, AGM, and networking drinks on 18 September, and the Clinical Summit on 19 November.Beyond ARCS, we cover the week’s biggest sector stories: PBS deferrals, new asthma treatments for kids, robotic surgery firsts, biotech highs and lows, and leadership shake-ups across pharma.Tune in for analysis, insights, and a clear-eyed look at what it all means for you.CTA: Be part of the conversation shaping the future of life sciences in Australia — join ARCS today

How do you know if a new product can be marketed in Australia? The answer lies in the very first questions you ask.In this episode of the Cognitio podcast, ARCS Australia CEO Tim Boyle sits down with Dr Helena Dickinson, a regulatory affairs consultant with over 30 years of experience in medicines and medical devices. Together, they unpack the critical steps in classifying a product and determining its eligibility for approval.Helena shares practical insights on:Why country of manufacture and GMP clearance are the first hurdles to clearHow ingredient names and monographs shape eligibilityThe importance of dosage forms and poison scheduling in classificationHow claims and indications can bump a product from listed to OTC—or OTC to prescriptionCommon pitfalls when relying on overseas approvalsWhether you’re working with listed medicines, OTCs, or prescription products, this episode offers a step-by-step framework to guide your initial review and avoid costly delays.🔗 Learn more about ARCS and join the community shaping the future of medicines, devices, and data at arcs.com.au.

This week in the ARCS Australia Weekly Medtech & Pharma Wrap we delve into the stories that are shaping our industry. From quantum blood testing and vaccination patches that are needle-free, through blockbuster drug wars, policy debates, and company culture – the picture is clear: innovation is racing, and access and capacity need to keep up.Watch the newest episode now and stay one step ahead of the trends that are shaping medicine in Australia and worldwide.

In this episode of Cognitio, ARCS CEO Tim Boyle is joined by Professor Andrew Wilson, Co-Director of the Menzies Centre for Health Policy and Economics at the University of Sydney and Chair of the Implementation Advisory Group for HTA Reform.Drawing on his deep experience as former Chair of the PBAC and now a central figure in shaping reform, Professor Wilson reflects on the challenges of translating more than 50 recommendations into meaningful change. He discusses the complexities of sequencing reforms, balancing equity and timely access, and the importance of collaboration across government, industry, clinicians, and consumers.Listeners will gain unique insight into the realities of HTA reform in Australia — what’s happening now, what lies ahead, and why implementation detail matters.This episode also features a message from our ARCS Partners, whose support helps drive conversations that advance professionalism and innovation in the life sciences.Stay tuned until the end for a clear call to action on how you can be part of the conversation shaping the future of healthcare by joining ARCS Australia.

In this Cognitio episode, host Tim Boyle is joined by Adele Barnard to explore the fast-changing world of implantable medical device regulation in Australia. Drawing on Adele’s first-hand industry experience, the episode unpacks the TGA’s definition of medical devices, the full lifecycle from pre-approval to post-market surveillance, and the critical steps that sponsors and manufacturers must navigate. Listeners will hear real-world case studies — from multimillion-dollar penalties to high-profile media scrutiny — that have shaped recent reforms. We look at how global alignment, stronger clinical evidence requirements, and robust registry data are redefining compliance, patient safety, and market access. Whether you’re in regulatory affairs, product development, or executive leadership, this is essential listening for staying ahead in the evolving MedTech regulatory landscape.

In this episode of Cognitio, ARCS Australia CEO Tim Boyle speaks with leadership and team performance coach Matt Brown about one of the defining capabilities of our time: resilience.Drawing on over 25 years of experience helping leaders and teams navigate disruption, Matt unpacks how to build resilience at both an individual and organisational level. From understanding the VUCA (Volatile, Uncertain, Complex, Ambiguous) world we work in, to using tools like mindfulness, gratitude, and purpose, this conversation offers practical, evidence-based strategies you can apply immediately.You’ll hear how psychological safety fuels performance, why resilience starts from the inside out, and the one simple habit Matt says every leader should try this week.Links and Resources:ARCS Australia – Learn more about our work and upcoming events.Unearth Your Resilience Program – Matt Brown (Insert actual link)ARCS Membership – Join the conversation. Join ARCS today.Subscribe & ReviewIf you enjoyed this episode, please subscribe to Cognitio on your preferred podcast platform and leave us a review—it helps more professionals discover these conversations.

In this episode of the Cognitio Podcast, we sit down with Brenton Judge, Executive General Manager at Hendon Semiconductors, to explore the real-world challenges and considerations in outsourced manufacturing. With over three decades of experience in large-scale operations across Asia and Australia, Brenton shares frank insights into what makes—or breaks—a vendor relationship.We cover:Why early vendor involvement matters more than everCommon pitfalls in product design, EMC compliance, and testabilityThe hidden costs of overseas manufacturingThe grey areas of IP ownership and test system controlWhat to look for in a genuine manufacturing partnershipWhether you're navigating contract manufacturing for the first time or rethinking your outsourcing model, this episode offers grounded advice that will help you de-risk your next product launch.

In this episode, ARCS CEO Tim Boyle speaks with Greg Taylor from the Copyright Agency about one of the most overlooked risks in the pharmaceutical and medtech sectors: copyright compliance. Greg unpacks what copyright means in an Australian context, how it applies to regulatory affairs, pharmacovigilance, and clinical research workflows, and why simply buying or accessing an article isn’t the same as having permission to share it.Through real-world examples and practical advice, this 25-minute episode highlights common myths, outlines licensing solutions tailored to the life sciences, and offers clear guidance on how to stay compliant — ethically and legally.Whether you work in a sponsor company, CRO, or advisory role, this is essential listening for anyone handling published literature in a professional setting.

What does it take to create a future-proof framework for data sharing in clinical research?In this episode of Cognitio, Tim Boyle is joined by Dr Lisa Eckstein, Program Director of CT:IQ, to unpack a major national initiative reshaping how Australian researchers think about data access, consent, and governance.Lisa shares insights from her work with the Australian Research Data Commons (ARDC) on the Clinical Research Data Sharing Frameworks project—covering everything from the development of the Informed PICF template to benchmarking ethics committee decision-making across the country.Whether you're a researcher, sponsor, or ethics reviewer, this conversation offers a timely look at the enablers and barriers to responsible data sharing, and how the sector can better align on legal, ethical, and participant-centred approaches.🎙️ Highlights include:Why outdated consent forms are holding research backThe push for “the ICH-GCP of data sharing”What ethics committees are getting right—and wrongTools and templates your team can use right nowTo learn more or access the tools discussed, visit ctiq.org.au or arcs.com.au.

🎧 Episode Description – Cognitio PodcastMentorship Matters – From Insight to ImpactPresented by ARCS AustraliaIn this episode of Cognitio, we explore the transformative power of mentorship with one of Australia’s most respected Medical Affairs professionals—Dr. Leon Rozen.Blending sharp insight, practical strategies, and a dash of Greek mythology, Leon unpacks what it really means to mentor and be mentored. From dismantling common myths to exploring modern approaches like reverse mentoring and coaching hybrids, this conversation moves beyond theory and into the reality of how people grow—together.Hosted by ARCS CEO Tim Boyle, this documentary-style episode draws on Leon’s decades of leadership and people development expertise to illuminate how mentorship shapes careers, builds confidence, and fosters capability across the life sciences sector.Whether you’re an emerging professional or a seasoned leader, this is your invitation to reflect on the role mentorship has played in your journey—and how you can pay it forward.🔗 Visit arcs.com.au to learn more about our leadership and mentoring programs.

In this special anniversary episode, ARCS CEO Tim Boyle takes listeners on a journey through the 40-year history of ARCS Australia—tracing its evolution from a volunteer-run group hosting wine and cheese nights to becoming the national peak body for life sciences professionals.Featuring the voices of founders, past presidents, long-time volunteers, and TGA collaborators, this episode reveals how ARCS was born out of frustration with regulatory uncertainty and grew through grassroots passion, professionalisation, and purposeful partnerships.Discover how ARCS has shaped careers, influenced regulation, and built a professional community dedicated to advancing innovation in healthcare—and why the next chapter may be the most exciting yet.🎧 Listen now to hear the story of ARCS—told by those who lived it.🔖 #ARCSAustralia #LifeSciences #RegulatoryAffairs #ClinicalResearch #ProfessionalDevelopment #ARCS40Years